Target the Biofilm - Transform the Outcome
Inoculus Ventures is a North Carolina-based biotechnology company developing enzyme-based therapies that target and disrupt bacterial biofilms the root cause of many chronic and treatment-resistant conditions.

Our first breakthrough therapeutic for chronic dry eye disease and blepharitis has been successfully licensed internationally. We are now advancing our platform to address other biofilm-driven challenges in human health.